At this point, most veterinarians are comfortable reaching for a JAK inhibitor when managing canine allergic dermatitis. Apoquel has been part of veterinary medicine for more than a decade, Zenrelia has rapidly entered the conversation as a newer alternative, and Numelvi is the newest entrant to the market. While all three reduce pruritus through JAK-STAT pathway inhibition, clinicians are increasingly recognizing that these drugs do not feel completely interchangeable in practice.

As more options become available, the question becomes less “Do JAK inhibitors work?” and more “Which JAK inhibitor may work best for this particular patient?”

Apoquel remains the most familiar option for many veterinarians because of its rapid onset and generally reliable efficacy. Many dogs experience noticeable improvement within hours of administration, which is one of the reasons the drug became so widely adopted so quickly. Apoquel primarily targets JAK1, although at higher or twice-daily exposure it likely affects additional JAK pathways as well.

One of the most useful clinical pearls with Apoquel is recognizing the “day 14 to day 28 rebound” that many clinicians encounter. A dog improves dramatically during the twice-daily loading phase, then becomes noticeably itchier after transitioning to once-daily maintenance dosing. Owners often interpret this as treatment failure, even though the drug may still be providing meaningful benefit. Recent discussions in veterinary dermatology have highlighted studies suggesting that nearly half of dogs may experience some degree of rebound during this transition.1

In practice, this becomes an important counseling point. Rather than abandoning Apoquel immediately when dogs worsen after transitioning to once-daily maintenance dosing, some patients may ultimately require long-term twice-daily administration to maintain adequate control. Although this approach is off-label, retrospective studies and clinical experience suggest it can be effective in dogs that remain poorly controlled on once-daily therapy.2 Some dermatologists also suspect that the improved efficacy observed with twice-daily dosing may reflect broader JAK pathway inhibition at higher drug exposure, although this remains more of a clinical observation than a definitively established mechanism.

Another useful clinical observation is that Apoquel sometimes underperforms in dogs whose atopic disease primarily manifests as otitis externa. Many clinicians have experienced patients whose generalized pruritus improves substantially while chronic ear inflammation persists.

Safety concerns surrounding Apoquel have softened considerably over the years. Early concerns regarding neoplasia have not been strongly supported in larger retrospective analyses. Current evidence suggests that papillomas and histiocytomas are the most commonly observed dermatologic masses associated with therapy, rather than aggressive malignancies.3 Still, many clinicians remain appropriately cautious about using any JAK inhibitor in patients with active cancer.

Zenrelia has generated substantial discussion because of both its efficacy and its vaccine warning. Unlike Apoquel, Zenrelia targets multiple JAK pathways, including JAK1, JAK2, and TYK2. Clinically, this broader activity may help explain why some veterinarians are seeing improved control in more inflammatory presentations or in dogs that have become difficult to control with Apoquel alone. There has also been growing interest in its use for chronic otitis.

The vaccine warning surrounding Zenrelia deserves context. The original concern stemmed from studies performed in immunologically naïve dogs that had never previously been vaccinated, which many clinicians would argue does not fully reflect real-world veterinary practice. More recent booster vaccination studies in previously vaccinated dogs failed to demonstrate clinically meaningful impairment in vaccine response, even at elevated doses.4 It is also worth noting that the United States is currently the only country still carrying this vaccine warning on the label. Canada has already softened its position and no longer recommends discontinuation around routine vaccination.

One particularly interesting observation with Zenrelia has been the consistency of itch control over time. Unlike Apoquel, there is no loading-dose transition. In comparative studies, itch scores continued improving over time rather than plateauing or rebounding. By day 112, substantially more dogs achieved well-controlled disease scores compared with Apoquel-treated patients.5 Clinically, this has led some veterinarians to view Zenrelia as a potentially stronger option for dogs with more severe inflammatory disease or for patients that lose control after the Apoquel loading phase ends.

Numelvi, Merck’s newly approved JAK inhibitor, is currently the least familiar simply because clinicians do not yet have extensive real-world experience with it. Like Apoquel, it is considered more JAK1 selective. One potentially important distinction, however, is its approval for dogs as young as six months of age, compared with the 12-month labeling restriction associated with Apoquel and Zenrelia.

At present, published data remain relatively limited compared with the older products. Early studies demonstrate significant improvement in pruritus compared with placebo, and the adverse effect profile appears similar to other drugs in the class. Importantly, current data do not suggest impaired vaccine response.6 Another practical point worth remembering is that Numelvi should be administered with food.

Cost inevitably enters these conversations as well, and the economics are often more nuanced than they initially appear. Dose frequency, tablet strengths, body weight, and long-term treatment strategy can all significantly impact real-world affordability for clients. As additional JAK inhibitors enter the market, it becomes increasingly important to evaluate cost based on the dosing approach a patient is actually likely to require rather than relying solely on headline pricing or marketing comparisons.

Ultimately, the growing number of JAK inhibitors is a positive development for veterinary medicine. Rather than viewing these drugs as direct replacements for one another, it is more useful to think about them as different tools within the same therapeutic category.

Apoquel remains an excellent and familiar option for rapid itch control. Zenrelia may offer advantages in more inflammatory or difficult-to-control cases, particularly involving ears. Numelvi may eventually carve out a niche in younger patients or in dogs where vaccine concerns remain top of mind.

The “best” JAK inhibitor will likely depend less on the label and more on the patient sitting in front of you.

References:

1. Olivry T, Lokianskiene V, Blanco A, et al. A randomised controlled trial testing the rebound-preventing benefit of four days of prednisolone during the induction of oclacitinib therapy in dogs with atopic dermatitis. Vet Dermatol. 2023;34(2):99-106. doi:10.1111/vde.13134. 
2. Denti D, Caldin M, Ventura L, De Lucia M. Prolonged twice-daily administration of oclacitinib for the control of canine atopic dermatitis: a retrospective study of 53 client-owned atopic dogs. Vet Dermatol. 2022;33(2):149-e38. doi:10.1111/vde.13053
3. Lancellotti BA, Angus JC, Edginton HD, Rosenkrantz WS. Age- and breed-matched retrospective cohort study of malignancies and benign skin masses in 660 dogs with allergic dermatitis treated long-term with versus without oclacitinib. J Am Vet Med Assoc. 2020;257(5):507-516. doi:10.2460/javma.257.5.507.
4. Fent GM, Jacela J, Plazola-Ortiz R, et al. Immunologic response to first booster vaccination in dogs treated with zenrelia™ (ilunocitinib tablets) at up to three times the recommended therapeutic dose compared to untreated controls. BMC Vet Res. 2025;21(1):481. doi:10.1186/s12917-025-04929-z.
5. Forster S, Boegel A, Despa S, Trout C, King S. Comparative efficacy and safety of ilunocitinib and oclacitinib for the control of pruritus and associated skin lesions in dogs with atopic dermatitis. Vet Dermatol. 2025;36(2):165-176. doi:10.1111/vde.13319.
6. Numelvi – atinvicitinib tablets. NADA 141-596. [Freedom of Information Summary for dogs]. Intervet Inc. 2026.